{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-128310","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2022-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.698285+00:00","generated_at":"2026-06-21T02:22:06.879075+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Onconova adds two independent directors with pharma R&D backgrounds","bullets":["Board expanded to eight; elected Peter Atadja (former Novartis Executive Director) and Trafford Clarke (former Eli Lilly Managing Director).","Atadja appointed Chair of Nominating & Corporate Governance; Clarke joins Compensation Committee.","Each receives standard non-employee director compensation plus one-time option to purchase 100,000 shares of common stock.","Atadja led discovery/development of first approved HDAC inhibitor (FARYDAK); Clarke spent 31 years at Eli Lilly in senior R&D roles."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-128310","json":"https://secwatch.observer/filing/0001104659-22-128310.json","markdown":"https://secwatch.observer/filing/0001104659-22-128310.md","text":"https://secwatch.observer/filing/0001104659-22-128310.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465922128310/0001104659-22-128310-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465922128310/tm2233068d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T02:22:06.879075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0317bbc3a2","claim":"Trafford Clarke was elected as Director at Traws Pharma, Inc..","evidence_excerpt":"elected Peter Atadja, Ph.D. and Trafford Clarke, Ph.D. as members of the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465922128310/0001104659-22-128310-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a4accd251b","claim":"Peter Atadja was elected as Director at Traws Pharma, Inc..","evidence_excerpt":"elected Peter Atadja, Ph.D. and Trafford Clarke, Ph.D. as members of the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465922128310/0001104659-22-128310-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}